AdaptHealth (AHCO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
Annual meeting scheduled for June 18, 2026, with voting on director elections, auditor ratification, and executive compensation (say-on-pay).
Proxy materials distributed electronically to enhance efficiency and sustainability.
Record date for voting is April 24, 2026, with 136,054,152 shares outstanding.
Voting matters and shareholder proposals
Shareholders will vote to elect nine directors for one-year terms, ratify KPMG LLP as auditor for 2026, and approve executive compensation in a non-binding advisory vote.
Board recommends voting in favor of all proposals.
Plurality voting for directors; majority of votes cast required for auditor ratification and say-on-pay.
No other business is expected at the meeting.
Board of directors and corporate governance
Board declassification completed; all directors now elected annually.
Nine director nominees, with a majority deemed independent under Nasdaq rules.
Board committees: Audit, Compensation, and Corporate Compliance & Governance, all with independent members.
Board leadership split between independent Chair and CEO.
Board and committees met five times in 2025; strong attendance.
Latest events from AdaptHealth
- Net revenue up 5.4% to $819.8M, but margin and net loss worsened amid higher costs.AHCO
Q1 20265 May 2026 - Record operational gains and exclusive payer contracts drive growth and portfolio focus.AHCO
Leerink Global Healthcare Conference 20269 Mar 2026 - Expanding market share and operational scale in sleep and respiratory care, with strong contract growth.AHCO
J.P. Morgan 2026 Global Leveraged Finance Conference3 Mar 2026 - Record patient growth and a major contract drove 2025, but a $128M impairment led to a net loss.AHCO
Q4 202524 Feb 2026 - Q2 revenue up 1.6%, net income up 39%, strong cash flow, and ongoing legal challenges.AHCO
Q2 20242 Feb 2026 - Five-point plan drives growth as respiratory and sleep outperform, while GLP-1 use rises among new CPAP patients.AHCO
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Q3 2024 returned to profitability with $22.9M net income and improved cash flow.AHCO
Q3 202416 Jan 2026 - Operational improvements and diabetes turnaround are central, with growth targeted for 2025-26.AHCO
Stifel 2024 Healthcare Conference13 Jan 2026 - Operational integration, segment focus, and payer partnerships drive stable, optimistic growth.AHCO
Bank of America Home Care Conference11 Jan 2026